Category Archives: Hypertension

Primary percutaneous coronary intervention (PPCI) procedures for ST-segment elevation myocardial infarction (STEMI) significantly decreased during the coronavirus disease 2019 (COVID-19) pandemic, particularly in patients with hypertension, according to a study published in the Journal of the American College of Cardiology. In this retrospective registry review, the data of 6609 patients with STEMI who underwent mechanical reperfusion at 77 centers across 18 countries were examined. This cohort included 3484 and 2811 patients (median age for both, 60 years) who underwent STEMI in 2019 and 2020, respectively. Continue reading →

CAESAREA, Israel and AGOURA HILLS, Calif., Dec. 2, 2020 /PRNewswire/ --V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today Continue reading →

The Pulmonary Arterial Hypertension (PAH) Therapeutics Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. Continue reading →

The Most Recent study on the Renovascular Hypertension Treatment Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. Continue reading →

The global Pulmonary Arterial Hypertension (PAH) Drugsmarketis comprehensively and Insightful information in the report, taking into consideration various factors such as competition, regional growth, segmentation, and Pulmonary Arterial Hypertension (PAH) DrugsMarket size by value and volume. This is an excellent research study specially compiled to provide the latest insights into critical aspects of the Pulmonary Arterial Hypertension (PAH) Drugsmarket Continue reading →

An analysis report published by DataIntelo is an in-depth study and detailed information regarding the market size, market performance and market dynamics of the Pulmonary Arterial Hypertension Treatment. The report offers a robust assessment of the Global Pulmonary Arterial Hypertension Treatment Market to understand the current trend of the market and deduces the expected market trend for the Pulmonary Arterial Hypertension Treatment market for the forecast period Continue reading →

Can J Respir Ther. 2020 Nov 26;56:1-9. Continue reading →

The Idiopathic Intracranial Hypertension Treatment Market grew in 2019, as compared to 2018, according to our report, Idiopathic Intracranial Hypertension Treatment Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Idiopathic Intracranial Hypertension Treatment Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025 Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically Continue reading →

SOUTH SAN FRANCISCO, Calif., Dec.4, 2020 /PRNewswire/ --Rigel Pharmaceuticals, Inc.(Nasdaq: RIGL) today announced that data related to TAVALISSE (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. The poster presentations will be made available on the event's website at https://www.hematology.org/meetings/annual-meetingon Saturday, December 5 at 7:30am PT. Rigel will present an analysis of long-term safety data on fostamatinib in more than 3,500 patients at various dosing regimens with immune thrombocytopenia (ITP) or rheumatoid arthritis (RA).Nonew safety signals norcumulative toxicity were observed with up to 62 months (5.2 years) of continuous treatment in ITP patients and up to 81 months (6.8 years) of continuous treatmentin RA patients Continue reading →

Day 29 of 30 Days of PH Topic: Dealing With The Elephant In The Room This is Skarlettes Story @skarletteisdead In December 2015, I was diagnosed with pulmonary hypertension and heart failure. My diagnosis did not come easily. Id been struggling for a long time and it took multiple doctors, three hospitals, seemingly endless tests, and a lot of hard conversations to finally find out what was wrong Continue reading →